{"organizations": [], "uuid": "424d6166bd54d430295fabd899a73386c75a4b18", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/3", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/26/globe-newswire-sol-gel-technologies-ltd-availability-of-its-annual-report-on-form-20-f-through-its-website.html", "country": "US", "domain_rank": 767, "title": "Sol-Gel Technologies Ltd. Availability of Its Annual Report on Form 20-F Through Its Website", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-27T00:05:00.000+03:00", "replies_count": 0, "uuid": "424d6166bd54d430295fabd899a73386c75a4b18"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/26/globe-newswire-sol-gel-technologies-ltd-availability-of-its-annual-report-on-form-20-f-through-its-website.html", "ord_in_thread": 0, "title": "Sol-Gel Technologies Ltd. Availability of Its Annual Report on Form 20-F Through Its Website", "locations": [], "entities": {"persons": [{"name": "patricia l. b", "sentiment": "none"}, {"name": "sol-gel", "sentiment": "none"}, {"name": "gilad mamlok", "sentiment": "none"}], "locations": [{"name": "israel", "sentiment": "none"}], "organizations": [{"name": "sol-gel technologies ltd", "sentiment": "negative"}, {"name": "sol-gel technologies ltd.", "sentiment": "negative"}, {"name": "globe newswire", "sentiment": "negative"}, {"name": "securities and exchange commission", "sentiment": "none"}, {"name": "sol-gel technologies sol-gel", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "NESS ZIONA, Israel, March 26, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ:SLGL), a clinical-stage dermatology company, announced today that it filed its Annual Report for 2017 on Form 20-F, containing audited financial statements for the year ended December 31, 2017, as filed with the Commission on March 26, 2018, which is available on its website ( http://www.sol-gel.com ). Shareholders may receive a hard copy of the annual report free of charge upon request.\nAbout Sol-Gel Technologies\nSol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gelâ€™s current product candidate pipeline consists of late-stage branded product candidates that leverage our proprietary, silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.\nFor further information, please contact:\nSol-Gel Contact:\nGilad Mamlok\nChief Financial Officer\n+972-8-9313433\nInvestor Contact:\nPatricia L. Bank\nWestwicke Partners\n+1-415-513-1284\npatti.bank@westwicke.com\nSource:Sol-Gel Technologies Ltd.", "external_links": ["https://www.globenewswire.com/Tracker?data=XvTTT5ocvbBvGHVQbVm9GRPBK0fgPAspBOlAetv9ornySP3uyONlZ4VLn-0uk0ANTKJdq0i9jVvd-rA7MdJcmeILVevQsEehjU8FSI5qwEE=", "https://www.globenewswire.com/NewsRoom/AttachmentNg/73d0b9a9-36b6-44a4-a813-d62f8e857f78"], "published": "2018-03-27T00:05:00.000+03:00", "crawled": "2018-03-27T01:27:47.001+03:00", "highlightTitle": ""}